It's an extremely good thing that money sometimes changes hands. Carl William Brown Read Stocks Aphorisms
Sponsored Links and Publicity
Everyone wants to believe that the $1 biotech stock they own today will be a $10 stock tomorrow. human genome is one of the great speculative success stories this year. so is vanda pharmaceuticals (vnda quote) and even, dare i say it, cell therapeutics. Carl William Brown
Bank of America Corporation (Bank of America) is a bank holding
company and a financial holding company. Through its banking
subsidiaries and various non-banking subsidiaries throughout the
United States and in selected international markets, it provides a
diversified range of banking and non-banking financial services and
products through three business segments: Global Consumer and Small
Business Banking, Global Corporate and Investment Banking and Global
Wealth and Investment Management. Bank of America operates in 50
states, the District of Columbia and more than 40 foreign countries.
Bank of America has 6,100 banking centers, approximately 18,700
automated teller machines (ATMs), nationwide call centers, and
online and mobile banking platforms. On January 1, 2009, Bank of
America announced the purchase of Merrill Lynch & Co., Inc. On July
1, 2008, Bank of America completed the acquisition of Countrywide
Citigroup Inc. (Citigroup) is a global diversified financial services holding company. The Company is engaged in providing a range of financial services to consumers and corporate customers. As of May 4, 2009, Citigroup had more than 200 million customer accounts and did business in more than 140 countries. Through its two operating units, Citicorp and Citi Holdings, Citigroup provides consumers, corporations, governments and institutions with a range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, and wealth management.In August 2009, the Company sold three credit card portfolios.
Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. Cell Therapeutics is developing pixantrone (BBR 2778), a deoxyribonucleic acid (DNA) major groove binder with an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. A new chemical compound for the treatment of non-Hodgkin’s lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed to improve activity and safety in treating cancers treated with the anthracycline family of anti-cancer agents. It is developing OPAXIO (paclitaxel poliglumex), which was previously referred to as XYOTAX, for the treatment of non-small cell lung cancer (NSCLC), and ovarian cancer.
Novavax, Inc. (Novavax) is a clinical-stage biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon preventive options for a range of infectious diseases. These vaccines leverage its virus-like particle (VLP) platform technology coupled with a disposable production technology. VLPs are genetically engineered three-dimensional nanostructures, which incorporate immunologically important lipids and recombinant proteins. Novavax’s VLPs resemble the virus but lack the genetic material to replicate the virus. Its production technology uses insect cells rather than chicken eggs or mammalian cells. The Company’s product targets include vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, Varicella Zoster, which causes shingles, and respiratory syncytial virus (RSV). This RSV vaccine was announced on October 30, 2008.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children’s nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline plc.
Immunomedics, Inc. is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed a number of advanced technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents. It has licensed its product candidate epratuzumab, to UCB S.A. (UCB), for the treatment of all autoimmune disease indications. Epratuzumab’s advanced clinical testing is for the treatment of systemic lupus erythematosus (SLE), and in non-Hodgkin’s lymphoma (NHL). It has retained the rights for epratuzumab in oncology indications, subject to UCB’s buy-in option, and is advancing trials in lymphoma and in childhood acute lymphoblastic leukemia (ALL), in cooperation with National Cancer Institute Study Groups.
Pramac SpA is an Italy-based company engaged in the manufacturing of the power generation equipment, materials handling equipment and photovoltaic components. The Company divides its activities into three business sectors: Power, which comprises generators for electric power, including low voltage portable generators and medium and high voltage generators; Handling, which includes the manufacturing and distribution of the machinery for handling logistic; and Ecopower for the photovoltaic components. The Company has six production plants in Italy, Spain, France, China, the USA and Switzerland. It operates worldwide through the distribution network of subsidiaries among which are: Pramac France SAS, Pramac Lifter GmbH, Pramac Group Scandinavia Aps, Pramac Lifter Afrique Trading Sarl, Masons Power Generators Ltd and Pramac Swiss SA, among others.
Corcept Therapeutics, Inc. is a United States-based pharmaceutical
company. The Company is involved in the discovery and development of
drugs that regulate the effects of cortisol or also known as the
stress hormone. Founded on 1998, it has focused its research and
clinical development activity on drugs that block the glucocorticoid
receptor or GR-II receptor, one of the bodys two receptors of
cotrisol. Korlym (mifepristone) is a cortisol receptor blocker
indicated to control hyperglycemia secondary to hypercortisolism in
adult patients with endogenous Cushing's syndrome who have type 2
diabetes mellitus or glucose intolerance and have failed surgery or
are not candidates for surgery.
ArQule, Inc. is a clinical-stage biotechnology company engaged in
the research and development of cancer therapeutics. It employs
technologies, such as its ArQule Kinase Inhibitor Platform to design
and develop drugs. Its product is ARQ 197, an orally administered
inhibitor of the c-Met receptor tyrosine kinase (c-Met). C-Met is a
target for cancer therapy, based on its multiple roles in cancerous
cell proliferation, tumor spread, new blood vessel formation and
resistance to certain drug therapies. It has licensed commercial
rights to ARQ 197 for human cancer indications to Daiichi Sankyo in
the United States, Europe, South America and the rest of the world,
excluding Japan and other Asian countries, where it has licensed
commercial rights to Kyowa Hakko Kirin. In August 2011, Kyowa Hakko
Kirin announced the initiation of the Phase III ATTENTION (Asian
Trial of Tivantinib plus Erlotinib vs. Erlotinib for NSCLC without
EGFR Mutation) trial of tivantinib in combination with erlotinib.
Albany Molecular Research, Inc. (AMRI) is a contract research and
manufacturing company. The Company provides customers with fully
integrated drug discovery, development and manufacturing services.
The Company operates in two segments: Large Scale Manufacturing
(LSM) and Discovery, Drug Development and Small Scale Manufacturing
(DDS). Its LSM segment activities include pilot to commercial scale
production of active pharmaceutical ingredients and intermediates,
sterile syringe and vial filling and high potency and controlled
substance manufacturing and its remaining activities, including drug
lead discovery, optimization, drug development, and small scale
commercial manufacturing represent its DDS business segment. AMRI
supplies a range of services and technologies that support the
discovery and development of pharmaceutical products and the
manufacturing of active pharmaceutical ingredients (API) and drug
product for existing and experimental new drugs.
Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. After completing various studies, analyses and other activities in response to the lorcaserin CRL, in December 2011, the Company resubmitted the lorcaserin NDA. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize lorcaserin in the United States and its territories and possessions, subject to the United States Food and Drug Administration (FDA) approval of the lorcaserin NDA. As of December 31, 2011, the Company’s earlier-stage programs included APD811, an internally discovered, orally available agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension.
Antigenics Inc. (Antigenics), is a biotechnology company focused on developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. The Company’s principal product candidate is Oncophage (vitespen), a patient-specific therapeutic cancer vaccine. Oncophage has been tested in Phase III clinical trials for the treatment of renal cell carcinoma, the common type of kidney cancer, and for the treatment of metastatic melanoma. It has also been tested in Phase I and Phase II clinical trials in a range of indications and is in a Phase II clinical trial in recurrent glioma, a type of brain cancer. The Company’s product candidate portfolio also includes QS-21 Stimulon adjuvant (QS-21), which is used in numerous vaccines, AG-707, a therapeutic vaccine program for the treatment of genital herpes and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas
Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage
biopharmaceutical company, engaged in developing and commercializing
therapies with a focus primarily in the areas of hematology-oncology
and urology. The Company’s product is apaziquone (formerly EOquin),
which is in two Phase 3 clinical trials for non-muscle invasive
bladder cancer under a collaboration with Allergan Inc. Another drug,
ozarelix is in a Phase 2 clinical trial for benign prostatic
hypertrophy (BPH). On December 15, 2008, Spectrum and Cell
Therapeutics, Inc. (CTI) partnered to form a joint venture, RIT
Oncology, LLC (RIT), to develop Zevalin ([90Y]-ibritumomab tiuxetan)
in the United States. Its subsidiaries include OncoRx Pharma Private
Limited, Spectrum Pharmaceuticals GmbH, RIT Oncology, LLC and
Spectrum Pharma Canada. During the year ended December 31, 2008, the
Company dissolved NeoJB LLC.
Brainstorm Cell Therapeutics Inc. (Brainstorm) is a
development-stage company. The Company is engaged in developing stem
cell therapeutic products based on technologies enabling the
in-vitro differentiation of bone marrow stem cells to neural-like
cells. The Company focuses on utilizing the patient’s own bone
marrow stem cells to generate neurotrophic factors (NTF) cells that
may provide treatment for amyotrophic lateral sclerosis (ALS),
parkinson’s disease (PD) and spinal cord injury. The Company’s
technology is based on the NurOwn products, an autologous cell
therapeutic modality, consisting of the extraction of the patient
bone marrow, processed into neuronal-like cells and re-implanted
into the patient’s muscles or brain.
Human Genome Sciences (HGS)is a commercially focused
biopharmaceutical company. The Company has three products in
late-stage clinical development: Albuferon for chronic hepatitis C,
LymphoStat-B for systemic lupus erythematosus and ABthraxtm for
inhalation anthrax. Albuferon and LymphoStat-B are progressing
toward commercialization. In December 2008, the Company reported
that Albuferon met its primary endpoint in the first of two Phase
III clinical trials in chronic hepatitis C. HGS also has several
drugs in earlier stages of clinical development for the treatment of
cancer, led by its TRAIL receptor antibody HGS-ETR1 and a
small-molecule antagonist of IAP (inhibitor of apoptosis) proteins.
Oculus Innovative Sciences, Inc. is a biopharmaceutical company that
develops, manufactures and markets a family of products, based on
its platform technology called Microcyn, intended to help prevent
and treat infections in chronic and acute wounds. Microcyn is a
non-irritating oxychlorine compound designed to treat a range of
pathogens, including viruses, fungi, spores and antibiotic-resistant
strains of bacteria, such as Methicillin-resistant Staphylococcus
aureus (MRSA), and Vancomycin-resistant Enterococcus (VRE), in
wounds. Its device product is cleared for sale in the United States
as a 510(k) medical device for wound cleaning, debridement,
lubricating, moistening and dressing; is a device under Conformite
Europeenne (CE) Mark in Europe; is approved by the State Food and
Drug Administration (SFDA), in China as a technology that reduces
the propagation of microbes in wounds and creates a moist
environment for wound healing, and is approved as a drug in India
UniCredit SpA is Italy-based holding company engaged in the
financial sector. The Company’s division model is based on four
business areas: Network Management Divisions; Centralized Product,
Key Business Functions; Global Service Factories, and Multi-Local
Approach. The Network Management Divisions consist of the retail
markets, corporate and private banking. Its Centralized Product, Key
Business Functions include markets and investment banking, asset
management, leasing, household financing, global transaction banking,
and retail marketing and segments. The Global Service Factories
provide, among others back office, credit collection, procurement
services and real estate for supplying network management divisions
and product factories with specialized services. The Multi-Local
Approach focuses on the relations between local banks and clients.
It operates in 22 European countries through the local banks, and it
also has offices and representatives in Asia and the United States.
ARENA Agroindustrie Alimentari SpA is an Italy-based food producer
for large retailers. Arena Agroindustrie Alimentari SpA is active in
the food sector, mainly in the poultry sector. It concentrates its
activity on the marketing of fresh poultry products. The Company has
four subsidiaries: Arena Alimentari Freschi SpA, Co dis al Srl,
Gelus NV and Interfin SpA.
Aedes SpA is an Italy-based real estate company. It is a co-investor and management company focused on two areas of business: property services and co-investments. The property services business includes management of property funds, carried out through two savings management companies: Aedes BPM Real Estate SGR SpA and Aedes Value Added SGR, and provision of property services, carried out through five companies: Aedes Servizi SpA, Aedes Project Srl, Aedes Agency Srl, Agora Srl and Unicenter Srl. It also provides a tailor-made management service at every stage of any real estate project, with an integrated range of services: asset management, fund management, advisory, development, project management, planning engineering, intermediation, shopping mall management and financial, administrative and corporate government services.
Gabetti Property Solutions SpA, is a real estate holding company engaged in the planning, development, construction, management, sale and leasing of real estate properties in Italy. The Company operates through four main business lines: Agency, with Gabetti Agency SpA and Tree Real Estate Srl, consisting in direct real estate agencies, for the corporate, fractioning, and luxury sectors, and in a franchising network for the retail sector. Finance, with Tree Finance Srl, for credit brokerage services in the retail, corporate, and insurance sectors; Technical Services, with the Abaco group and Patrigest SpA, for services in the due diligence, property and facility management, consulting & advisory, ITC services B2B, energy efficiency certifications, real estate valuation and advisory, feasibility studies, and market analysis sectors; and Investment & Property, with La Gaiana SpA, for real estate trading and development investment activities, in Italy and abroad.
GEMINA Generale Mobiliare Interessenze Azionarie SpA (GEMINA) is an Italy-based investment holding company. The Company’s activities are structured of investments in the companies from four segments: airport activities; electric energy; air traffic control system, and others. In the airport activities segment, GEMINA is present by direct interests held in Aeroporti di Roma SpA (95.76%) , which manages airports in Rome. In the electric energy sector, it operates through the interests held in Sistemi di Energia SpA (45.55%). In the air traffic control system segment, the Company is active through interests held in S.I.T.T.I. SpA (40%). The company is present also in other sector through interests held in Pentar SpA (20.35%).
L'aviditą č il pungolo dell'operositą. David Hume and C.W. Brown Read Money Quotations
DAIMON NEWS ENGLISH QUOTES HOME PAGE
|Daimon Club||Daimon People||Daimon Arts||Daimon News||Daimon Magik|
|Daimon Guide||Daimon Library||C.W. Brown||Banner Exchange||Daimon Humor|